Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Dogwood Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 14 | 13 | −1 |
| Shares | 887.6K | 1.00M | +115.3K (+13.0%) |
| Value | $5.58M | $5.30M | −$278.0K (−5.0%) |
New holders (3)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Captrust Financial Advisors | 40,145 | $212.0K | 0.00% |
| Millennium Management LLC | 28,781 | $152.0K | 0.00% |
| Royal Bank of Canada | 1,000 | $5.00K | 0.00% |
Sold out (4)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| UBS Group AG | 13,316 | $84.0K |
| Virtu Financial LLC | 13,110 | $82.0K |
| Citadel Advisors LLC | 10,100 | $64.0K |
| Northwestern Mutual Wealth Management Co | 750 | $5.00K |